Citigroup’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4M | Hold |
50,000
| – | – | ﹤0.01% | 2132 |
|
|
2025
Q4 | $4.26M | Buy |
+50,000
| New | +$4.1M | ﹤0.01% | 2136 |
|
|
2025
Q2 | – | Sell |
-60,000
| Closed | -$4.35M | – | 5725 |
|
|
2025
Q1 | $4.35M | Hold |
60,000
| – | – | ﹤0.01% | 2023 |
|
|
2024
Q4 | $4.44M | Sell |
60,000
-22,500
| -27% | -$1.57M | ﹤0.01% | 2095 |
|
|
2024
Q3 | $5.44M | Buy |
+82,500
| New | +$5.99M | ﹤0.01% | 1775 |
|
|
2022
Q1 | – | Sell |
-129,900
| Closed | -$16.8M | – | 6395 |
|
|
2021
Q4 | $16.8M | Sell |
129,900
-96,000
| -42% | -$11.2M | 0.01% | 1096 |
|
|
2021
Q3 | $25.6M | Buy |
+225,900
| New | +$25.8M | 0.02% | 857 |
|
|
2021
Q1 | – | Sell |
-87,500
| Closed | -$7.98M | – | 6581 |
|
|
2020
Q4 | $7.98M | Sell |
87,500
-110,300
| -56% | -$9.15M | ﹤0.01% | 1752 |
|
|
2020
Q3 | $15.8M | Buy |
197,800
+85,000
| +75% | +$6.63M | 0.01% | 1045 |
|
|
2020
Q2 | $7.8M | Sell |
112,800
-22,200
| -16% | -$1.58M | 0.01% | 1500 |
|
|
2020
Q1 | $8.49M | Buy |
135,000
+33,300
| +33% | +$2.4M | 0.01% | 1272 |
|
|
2019
Q4 | $7.91M | Sell |
101,700
-19,800
| -16% | -$1.55M | 0.01% | 1667 |
|
|
2019
Q3 | $8.91M | Sell |
121,500
-89,100
| -42% | -$6.26M | 0.01% | 1481 |
|
|
2019
Q2 | $13M | Buy |
210,600
+70,500
| +50% | +$4.26M | 0.01% | 1215 |
|
|
2019
Q1 | $8.94M | Buy |
140,100
+30,600
| +28% | +$1.75M | 0.01% | 1343 |
|
|
2018
Q4 | $5.59M | Sell |
109,500
-106,500
| -49% | -$5.39M | 0.01% | 1718 |
|
|
2018
Q3 | $12.5M | Buy |
216,000
+103,200
| +91% | +$5.05M | 0.01% | 1133 |
|
|
2018
Q2 | $5.47M | Buy |
112,800
+43,500
| +63% | +$2.03M | 0.01% | 1749 |
|
|
2018
Q1 | $3.22M | Sell |
69,300
-8,400
| -11% | -$365K | ﹤0.01% | 2166 |
|
|
2017
Q4 | $2.92M | Buy |
77,700
+17,700
| +30% | +$650K | ﹤0.01% | 2312 |
|
|
2017
Q3 | $2.19M | Buy |
60,000
+14,400
| +32% | +$549K | ﹤0.01% | 2573 |
|
|
2017
Q2 | $1.8M | Sell |
45,600
-331,800
| -88% | -$12.1M | ﹤0.01% | 2700 |
|
|
2017
Q1 | $11.8M | Buy |
377,400
+159,600
| +73% | +$5M | 0.01% | 1025 |
|
|
2016
Q4 | $6.8M | Buy |
217,800
+131,400
| +152% | +$4.26M | 0.01% | 1521 |
|
|
2016
Q3 | $3.47M | Buy |
86,400
+22,500
| +35% | +$847K | ﹤0.01% | 2011 |
|
|
2016
Q2 | $2.12M | Sell |
63,900
-23,700
| -27% | -$811K | ﹤0.01% | 2294 |
|
|
2016
Q1 | $2.58M | Buy |
87,600
+86,700
| +9,633% | +$2.39M | ﹤0.01% | 2208 |
|
|
2015
Q4 | $24K | Sell |
900
-900
| -50% | -$23.4K | ﹤0.01% | 6386 |
|
|
2015
Q3 | $43K | Buy |
1,800
+1,200
| +200% | +$29K | ﹤0.01% | 5530 |
|
|
2015
Q2 | $14K | Buy |
+600
| New | +$13.5K | ﹤0.01% | 6293 |
|
|
2014
Q2 | – | Sell |
-900,000
| Closed | -$11.1M | – | 7165 |
|
|
2014
Q1 | $11.1M | Buy |
+900,000
| New | +$10.4M | 0.01% | 1075 |
|
|
2013
Q3 | – | Sell |
-147,000
| Closed | -$1.65M | – | 6839 |
|
|
2013
Q2 | $1.65M | Buy |
+147,000
| New | +$1.74M | ﹤0.01% | 2514 |
|
Other funds holding EW
VCM
VPM
Citigroup's EW Position: Q1 2026 in Review
Citigroup increased its Edwards Lifesciences (EW) stake by 27% in Q1 2026, buying an estimated $14M and bringing the position to 789,574 shares worth $63.2M. The position accounts for 0.03% of the portfolio, ranked #556.
Citigroup first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $108M in Q2 2025. 1,284 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Citigroup held 789,574 shares of Edwards Lifesciences worth $63.2M as of Q1 2026.
- Citigroup bought 169,775 Edwards Lifesciences shares in Q1 2026, an estimated $14M.
- Edwards Lifesciences made up 0.03% of Citigroup's portfolio in Q1 2026, its #556 holding.
- Citigroup first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
- Citigroup's Edwards Lifesciences position peaked at $108M in Q2 2025.
- 1,284 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.